Received Feb 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | IM / RA |
Bilateral eye inflammation; Bilateral eye tearing; Bilateral eye redness; This non-serious case was reported by a consumer via call center representative and described the occurrence of eye inflammation in a male patient who received Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included eye operation (had 23 eye surgeries in his lifetime due to a problem with his eyes since birth). On 24-AUG-2024, the patient received the 1st dose of Shingrix (intramuscular, right deltoid). In SEP-2024, 5 weeks after receiving Shingrix, the patient experienced eye inflammation (Verbatim: Bilateral eye inflammation), eyes tearing (Verbatim: Bilateral eye tearing) and eye redness (Verbatim: Bilateral eye redness). The outcome of the eye inflammation, eyes tearing and eye redness were not resolved. It was unknown if the reporter considered the eye inflammation, eyes tearing and eye redness to be related to Shingrix. It was unknown if the company considered the eye inflammation, eyes tearing and eye redness to be related to Shingrix. Additional Information: GSK Receipt Date: 24-JAN-2025 The reporter was the patient who had received his first dose of Shingrix on 24th August 2024 and 5 weeks later had developed bilateral eye redness, tearing, and inflammation symptoms that had not resolved. The patient stated he had been to the ophthalmologist 6 times since having the vaccine. The patient also told that he had 23 eye surgeries in his lifetime due to a problem with his eyes since birth.
Medical History/Concurrent Conditions: Eye operation (had 23 eye surgeries in his lifetime due to a problem with his eyes since birth)